Oral complications of HIV disease

Clinics

Volumn 64, Issue 5, 2009, Pages 459-470

  Leao, Jair C ^a   Ribeiro, Camila M B ^a   Carvalho, Alessandra A T ^a   Frezzini, Cristina ^b   Porter, Stephen ^b  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

AIDS; HIV; Mouth; Oral diseases; Oral manifestations

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; CHILD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUTH DISEASE; REVIEW;

ADULT; ANTI-HIV AGENTS; CHILD; HIV INFECTIONS; HUMANS; MOUTH DISEASES;

EID: 67749111412     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322009000500014     Document Type: Review

References (130)

1. Frezzini C, Leao JC, Porter S. Current trends of HIV disease of the mouth. J Oral Pathol Med. 2005;34:513-31.
2. Ascher MS, Sheppard HW. AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol 1988; 73: 165-7.
3. Health protection agency. Evidence of continuing increase in the HIV prevalence among injecting drug users in England and Wales. CDR Weekly. 2006; 16: 51.
4. UNAIDS. Report on the Global AIDS epidemic 2007. WHO 2007.
5. NACO - National AIDS Control Organization (2004). Combating HIV/AIDS in India. October 2003. Available from: .
6. UNAIDS. UNAIDS and the Joint United Nations Programme on HIV/AIDS. Children and AIDS: Second stocktaking report. Actions and progress. April 2008.
7. Kamps BS; Hofmann C. In: Hoffmann C, Rockstroh JK; Kamps BS. HIV Medicine 2007; Flying Publisher 15th Edition; p. 28. Avalilable from .
8. Horowitz HW, Telzak EE, Sepkowitz KA, Wormser GP. Human immunodeficiency virus infection, Part I. Dis Mon. 1998; 44: 545-606.
9. Rothenberg RB, Scarlett M, del Rio C, Reznik D, O'Daniels C. Oral transmission of HIV. AIDS. 1998; 12: 20: 95-105.
10. Najioullah F, Barlet V, Renaudier P, Guitton C, Crova P, Guérin JC, et al. Failure and success of HIV tests for the prevention of HIV-1 transmission by blood and tissue donations. J Med Virol. 2004; 73: 347-9.
11. Metsch LR, Pereyra M, Purcell DW, Latkin CA, Malow R, Gómez CA, et al. Correlates of lending needles/syringes among HIV-seropositive injection drug users. J Acquir Immune Defic Syndr 2007; 1; 46 Suppl 2: S72-9.
12. Salvatori F, De Martino M, Galli L, Vierucci A, Chieco-Bianchi L, De Rossi A. Horizontal transmission of human immunodeficiency virus type 1 from father to child. AIDS Res Hum Retroviruses. 1998; 14: 1679-85.
13. French MA, Herring BL, Kaldor JM, Sayer DC, Furner V, de Chaneet CC, et al. Intrafamilial transmission of HIV-1 infection from individuals with unrecognized HIV-1 infection. AIDS. 2003; 17: 1977-81.
14. Fraser VJ, Powderly WG. M. Risks of HIV infection in the health care setting. Annual Review of Medicine. 1995; 46: 203-11.
15. Marcus R, Kay K, Mann JM. Transmission of human immunodeficiency virus (HIV) in health-care settings worldwide. Bull World Health Organ. 1989; 67: 577-82.
16. Scully C, Porter S. HIV topic update: oro-genital transmission of HIV. Oral Dis. 2000;:92-8.
17. Campo J, Perea MA, del Romero J, Cano J, Hernando V, Bascones A. Oral transmission of HIV, reality or fiction? An update. Oral Dis. 2006; 12: 219-28.
18. Stahl-Hennig C, Steinman RM, Tenner-Racz K, Pope M, Stolte N, Mätz-Rensing K, et al. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science. 1999; 285: 1261-5.
19. Scully C, Greenspan JS. Human immunodeficiency virus (HIV) transmission in dentistry. J Dent Res. 2006; 85: 794-800.
20. The Lancet. Risk of HIV transmission during dental treatment [editorial]. Lancet. 1992; 340: 1259-60.
21. Health protection agency. Eye of the needle. Surveillance of Significant Occupational Exposure to Bloodborne Viruses in Health Care Workers. Centre for Infections; England, Wales and Northern Ireland Seven Year Report: January 2005:1-26
22. Moutsopoulos NM, Greenwell-Wild T, Wahl SM. Differential mucosal susceptibility in HIV-1 transmission and infection. Adv Dent Res. 2006; 19: 52-6.
23. Chua AC, Leo YS, Lee CC. Building partnerships to address the HIV epidemic. Singapore Med J 2008; 49(5): 376-9.
24. Medley GF, Billard L, Cox DR, Anderson RM. The distribution of the incubation period for the acquired immunodeficiency syndrome (AIDS). Proc R Soc Lond B Biol Sci. 1988; 233: 367-77.
25. Cooper DA, Gold J, Maclean P, Donovan B, Finlayson R, Barnes TG, et al. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet. 1985; 1: 537-40.
26. Miró JM, Sued O, Plana M, Pumarola T, Gallart T. Advances in the diagnosis and treatment of acute human immunodeficiency virus type 1 (HIV-1) infection. Enferm Infecc Microbiol Clin. 2004; 22: 643-59.
27. Jeeninga RE, Westerhout EM, van Gerven ML, Berkhout B. HIV-1 latency in actively dividing human T cell lines. Retrovirology. 2008; 5: 37.
28. Han Y, Wind-Rotolo M, Yang HC, Siliciano JD, Siliciano RF: Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol. 2007,5:95-106.
29. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. New England Journal of Medicine. 1998,339:33-39.
30. Greenspan D, Komaroff E, Redford M, Phelan JA, Navazesh M, Alves ME, et al. Oral mucosal lesions and HIV viral load in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr. 2000; 25: 44-50.
31. Coogan MM, Greenspan J, Challacombe SJ. Oral lesions in infection with human immunodeficiency virus. Bull World Health Organ. 2005; 83: 700-6.
32. Challacombe S. Revised classification of HIV--associated oral lesions. Br Dent J. 1991. 20; 170: 305-6.
33. Coulter ID, Heslin KC, Marcus M, Hays RD, Freed J, Der-Martirosia C, et al. Associations of self-reported oral health with physical and mental health in a nationally representative sample of HIV persons receiving medical care. Qual Life Res. 2002; 11: 57-70.
34. Stevenson M. HIV-1 pathogenesis. Nat Med. 2003; 9: 853-60.
35. Scully C, Dios P. Orofacial effects of antiretroviral therapies. Oral Diseases 2001; 7(4):205-210.
36. d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med. 2005;28; 165: 416-23. Erratum in: Arch Intern Med 2005; 165: 1200.
37. Hoffmann C, Mulcahy F. In: Hoffmann C, Rockstroh JK, Kamps BS. HIV Medicine 2007; Flying Publisher 15th Edition; p. 89. Avalilable from .
38. Williams IG. Enfuvirtide (Fuzeon): the first fusion inhibitor. Int J Clin Pract 2003; 57: 890-7.
39. Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G; Sonnerborg A. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. Clinical Science. AIDS. 2002; 16: 1039-44.
40. Tang JW, Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol. 2004; 30:1-10.
41. James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg. 2002; 28: 979-86.
42. Stankov MV, Behrens GM. HIV-therapy associated lipodystrophy: experimental and clinical evidence for the pathogenesis and treatment. Endocr Metab Immune Disord Drug Targets. 2007; 7: 237-49.
43. Orlando G, Guaraldi G, De Fazio D, Rottino A, Grisotti A, De Santis G, et al. Long-term psychometric outcomes of facial lipoatrophy therapy: forty-eight-week observational, nonrandomized study. AIDS Patient Care STDS. 2007; 21: 833-42.
44. Hodgson TA, Rachanis CC. Oral fungal and bacterial infections in HIV-infected individuals: an overview in Africa. Oral Dis. 2002; 8: 80-7.
45. Wood R.Management of HIV and AIDS in the African context. Oral Dis. 2002;8 Suppl 2:32-3.
46. Barasch A, Safford MM, Dapkute-Marcus I, Fine DH. Efficacy of chlorhexidine gluconate rinse for treatment and prevention of oral candidiasis in HIV-infected children: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 97: 204-7.
47. Campo J, Del Romero J, Castilla J, Garcia S, Rodriguez C, Bascones A. Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. J Oral Pathol Med. 2002; 31: 5-10.
48. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the Drug Resistance Mutations in HIV-1: 2005.Top HIV Med. 2005; 13: 51-7.
49. Sroussi HY, Epstein JB.Changes in the pattern of oral lesions associated with HIV infection: implications for dentists. J Can Dent Assoc. 2007; 73: 949-52.
50. Sterne JA, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005; 366: 378-84.
51. Porter SR, Scully C. HIV topic update: protease inhibitor therapy and oral health care. Oral Dis. 1998; 4: 159-63.
52. Ceballos-Salobrena A, Gaitan-Cepada LA, Ceballos-Carcia L, Lezema-Del Valle D. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patients Care STDS. 2000; 14: 627-35.
53. Tukutuku K, Muyembe-Tamfum L, Kayembe K, Odio W, Kandi K, Ntumba M. Oral manifestations of AIDS in a heterosexual population in a Zaire hospital. J Oral Pathol Med. 1990; 19: 232-4.
54. Reichart PA. Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi's sarcoma. Med Microbial Immunol. 2003; 192: 165-69.
55. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr. Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 89: 299-304.
56. EC-Clearinghouse on oral problems related to HIV infection and WHO collaborating centre on oral manifestations of the human immunodeficiency virus. Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med. 1993; 22: 289-91.
57. Ramos-Gomez F, Flaitz C, Catapano P. Classification, diagnostic criteria, and treatment recommendations for orofacial manifestations in HIV-infected paediatric patients. J Clin Pediatr Dent. 1999; 23: 85-96.
58. Flint S, Glick M, Patton L, Tappuni A, Shirlaw P, Robinson P. Consensus guidelines on quantifying HIV related oral mucosal disease. Oral Dis. 2002; 8(Suppl. 2):115-9.
59. Tappuni AR, Fleming GJ. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 200; 92: 623-8.
60. Patton LL, Phelan JA, Ramos-Gomez FJ, Nittayananta W, Shiboski CH, Mbuguye TL. Prevalence and classification of HIV-associated oral lesions. Oral Dis. 2002; 8(Suppl. 2):98-109.
61. Reichart PA. Infections of the mouth mucosa (I). HIV infection - an epidemiological, clinical and therapeutic update. Mund Kiefer Gesichtschir. 1999;3: 236-41.
62. Blignaut E, Messer S, Hollis RJ, Pfaller MA. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infect Dis. 2002; 44: 169-74.
63. Chidzonga MM, Mwale M, Malvin K, Martin JN, Greenspan JS, Shiboski CH. Oral candidiasis as a marker of HIV disease progression among Zimbabwean women. J Acquir Immune Defic Syndr. 2008; 47: 579-84.
64. Ranganathan K, Hemalatha R. Oral lesions in HIV infection in developing countries: an overview. Adv Dent Res. 2006; 19: 63-8.
65. Muzyka BC, Kamwendo L, Mbweza E, Lopez NB, Glick M, Matheson PB, et al. Prevalence of HIV-1 and oral lesions in pregnant women in rural Malawi. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 92: 56-61.
66. Bendick C, Scheifele C, Reichart PA. Oral manifestations in 101 Cambodians with HIV and AIDS. J Oral Pathol Med. 2002; 31: 1-4.
67. Chidzonga MM. HIV/AIDS orofacial lesions in 156 Zimbabwean patients at referral oral and maxillofacial surgical clinics. Oral Dis. 2003; 9: 317-22.
68. Naidoo S, Chikte U. Oro-facial manifestations in paediatric HIV: a comparative study of institutionalized and hospital outpatients. Oral Dis. 2004; 10: 13-8.
69. Pongsiriwet S, Iamaroon A, Kanjanavanit S, Pattanaporn K, Krisanaprakornkit S. Oral lesions and dental caries status in perinatally HIV-infected children in Northern Thailand. Int J Paediatr Dent. 2003; 13: 180-5.
70. Fonseca R, Cardoso AS, Pomarico I. Frequency of oral manifestations in children infected with human immunodeficiency virus. Quintessence Int. 2000; 31:419-22.
71. Magalhães MG, Bueno DF, Serra E, Gonçalves R. Oral manifestations of HIV positive children. J Clin Pediatr Dent. 2001; 25: 103-6.
72. Khongkunthian P, Grote M, Isaratanan W, Piyaworawong S, Reichart PA. Oral manifestations in 45 HIVpositive children from Northern Thailand. J Oral Pathol Med. 2001; 30: 549-52.
73. Butt FM, Vaghela VP, Chindia ML. Correlation of CD4 counts and CD4/CD8 ratio with HIV-infection associated oral manifestations. East Afr Med J. 2007; 84:383-8.
74. Nittayananta W, Chanowanna N, Sripatanakul S, Winn T. Risk factors associated with oral lesions in HIVinfected heterosexual people and intravenous drug users in Thailand. J Oral Pathol Med. 2001; 30: 224-30.
75. Lin HC, Corbet EF, Lo EC. Oral mucosal lesions in adult Chinese. J Dent Res 2001; 80: 1486-90.
76. Arendorf T, Holmes H. Oral manifestations associated with human immunodeficiency virus (HIV) infection in developing countries - are there differences from developed countries? Oral Dis. 2000; 6: 133-5.
77. Greenspan JS, Greenspan D. The epidemiology of the oral lesions of HIV infection in the developed world. Oral Dis. 2002;8(Suppl. 2):34-9.
78. Patton L, Hill C. Sensitivity, specificity, and positive predictive value of oral oppurtunistic infections in adults with HIV/AIDS as markers of immune suppression and viral burden. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 90: 182-8.
79. Rahman MA, Kingsley LA, Breinig MK, Ho M, Armstrong JA, Atchison RW, et al. Enhanced antibody responses to Epstein-Barr virus in HIV-infected homosexual men. J Infect Dis. 1989; 159: 472-9.
80. Eyeson JD, Tenant-Flowers M, Cooper DJ, Johnson NW, Warnakulasuriya KA. Oral manifestations of an HIV positive cohort in the era of highly active antiretroviral therapy (HAART) in South London. J Oral Pathol Med. 2002; 31: 169-74.
81. Walling DM, Flaitz CM, Nichols CM, Hudnall SD, Adler-Storthz K. Persistent productive Epstein-Barr virus replication in normal epithelial cells in vivo. J Infect Dis. 2001; 184: 1499-507.
82. Walling DM, Flaitz CM, Nichols CM. Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir. J Infect Dis. 2003; 188: 883-90.
83. Martró E, Esteve A, Schulz TF, Sheldon J, Gambús G, Muñoz R, et al. Risk factors for human Herpesvirus 8 infection and AIDS-associated Kaposi's sarcoma among men who have sex with men in a European multicentre study. Int J Cancer. 2007; 120: 1129-35.
84. Schöfer H, Sachs D. In: Hoffmann C, Rockstroh JK; Kamps BS. HIV Medicine 2007; Flying Publisher 15th Edition; p. 477. Avalilable from .
85. Leão JC, Hinrichsen SL, de Freitas BL, Porter SR. Human herpes virus 8 and Kaposi's sarcoma. Rev Assoc Med Bras.1999; 45: 55-62.
86. Holmes HK, Stephen LX. Oral lesions of HIV infection in developing countries. Oral Dis. 2002; 8(Suppl. 2):40-3.
87. Jacobson LP, Yamashita TE, Detels R, Margolick JB, Chmiel JS, Kingsley LA, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1999;21 Suppl 1:S34-41.
88. Krown SE. Management of Kaposi's sarcoma: the role of interferon and thalidomide. Curr Opin Oncol. 2001; 13: 347-81.
89. Thomas JO. Acquired immunodeficiency syndrome-associated cancers in Sub-Saharan Africa. Semin Oncol. 2001; 28: 198-206.
90. Ramírez-Amador V, Esquivel-Pedraza L, Lozada-Nur F, De la Rosa-García E, Volkow-Fernández P, Súchil-Bernal L, et al. Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial. Oral Oncol. 2002; 38: 460-7.
91. Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur J Cancer. 2001;37: 1288-95.
92. Feller L, Masipa J, Wood N, Raubenheimer E, Lemmer J. The prognostic significance of facial lymphoedema in HIV-seropositive subjects with Kaposi sarcoma. AIDS Res Ther 2008; 5: 2.
93. Caccialanza M, Marca S, Piccinno R, Eulisse G. Radiotherapy of classic and human immunodeficiency virus-related Kaposi's sarcoma: results in 1482 lesions. J Eur Acad Dermatol Venereol 2008; 22: 297-302.
94. Convissar RA. Laser palliation of oral manifestations of human immunodeficiency virus infection. J Am Dent Assoc. 2002; 133: 591-8;quiz 624-5.
95. Podzamczer D, Miralles P, La Calle Md M, Zarco C, Berenguer J, López Aldeguer J, et al. Recommendations of GESIDA/Spanish National Plan of AIDS on diagnosis and treatment of Kaposi's sarcoma and cervical cancer in HIV-infected patients. Med Clin (Barc). 2002; 118: 788-95.
96. Dezube BJ. Management of AIDS-related Kaposi's sarcoma: advances in target discovery and treatment. Expert Rev Anticancer Ther.2002; 2: 193-200.
97. Coutlée F, Trottier AM, Ghattas G, Leduc R, Toma E, Sanche G, et al. Risk factors for oral human papillomavirus in adults infected and not infected with human immunodeficiency virus. Sex Transm Dis. 1997; 24: 23-31.
98. Syrjanen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005; 32(Suppl 1):S59-66.
99. Kreimer AR, Alberg AJ, Daniel R, Gravitt PE, Viscidi R, Garrett ES, et al. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis. 2004; 189: 686-98.
100. Arora A, Chiao E, Tyring SK. AIDS malignancies. Cancer Treat Res. 2007; 133:21-67.
101. Cameron JE, Mercante D, O'Brien M, Gaffga AM, Leigh JE, Fidel PL Jr, et al. The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults. Sex Transm Dis. 2005; 32: 703-9.
102. Robinson PG. The significance and management of periodontal lesions in HIV infection. Oral Dis. 2002;8 Suppl 2:91-7.
103. Teanpaisan R, Douglas CW, Nittayananta W. Isolation and genotyping of black-pigmented anaerobes from periodontal sites of HIV-positive and non-infected subjects in Thailand. J Clin Periodontol. 2001; 28: 311-8.
104. Narani N, Epstein JB. Classifications of oral lesions in HIV infection. J Clin Periodontol. 2001; 28: 137-45.
105. Ranganathan K, Reddy BV, Kumarasamy N, Solomon S, Viswanathan R, Johnson NW. Oral lesions and conditions associated with human immunodeficiency virus infection in 300 south Indian patients. Oral Dis. 2000; 6: 152-57.
106. Flaitz C, Wullbrandt B, Sexton J, Bourdon T, Hicks J. Prevalence of orodental findings in HIV-infected Romanian children. Pediatr Dent. 2001; 23: 44-50.
107. Robinson PG, Boulter A, Birnbaum W, Johnson NW. A controlled study of relative periodontal attachment loss in people with HIV infection. J Clin Periodontol. 2000; 27: 273-6.
108. Chhieng DC, Argosino R, McKenna BJ, Cangiarella JF, Cohen JM. Utility of fine-needle aspiration in the diagnosis of salivary gland lesions in patients infected with human immunodeficiency virus. Diagn Cytopathol. 1999; 21: 260-4.
109. Mandel L. Ultrasound findings in HIV-positive patients with parotid gland swellings. J Oral Maxillofac Surg. 2001; 59: 283-6.
110. Mandel L, Kim D, Uy C. Parotid gland swelling in HIV diffuse infiltrative CD8 lymphocytosis syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998; 85:565-8.
111. Williams FM, Cohen PR, Jumshyd J, Reveille JD. Prevalence of the diffuse infiltrative lymphocytosis syndrome among human immunodeficiency virus type 1- positive outpatients. Arthritis Rheum. 1998; 41: 863-8.
112. Dave SP, Pernas FG, Roy S. The benign lymphoepithelial cyst and a classification system for lymphocytic parotid gland enlargement in the pediatric HIV population. Laryngoscope. 2007; 117: 106-13.
113. Navazesh M, Mulligan R, Barrón Y, Redford M, Greenspan D, Alves M, et al. A 4-year longitudinal evaluation of xerostomia and salivary gland hypofunction in the Women's Interagency HIV Study participants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003; 95: 693-8.
114. Valentine C, Deenmamode J, Sherwood R. Xerostomia associated with didanosine. Lancet. 1992; 340: 1542-3.
115. Younai FS, Marcus M, Freed JR, Coulter ID, Cunningham W, Der-Martirosian C, et al. Self-reported oral dryness and HIV disease in a national sample of patients receiving medical care. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 92:629-36.
116. Mandel L, Surattanont F. Regression of HIV parotid swellings after antiviral therapy: case reports with computed tomographic scan evidence. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002; 94: 454-9.
117. Beitler JJ, Smith RV, Brook A, Edelman M, Sharma A, Serrano M, et al. Benign parotid hypertrophy on+HIV patients: limited late failures after external radiation. Int J Radiat Oncol Biol Phys. 1999; 45: 451-5.
118. Turner MD, Ship JA. Dry mouth and its effects on the oral health of elderly people. J Am Dent Assoc 2007 Sep;138 Suppl:15S-20S. Review. Erratum in: J Am Dent Assoc. 2008; 139: 252-3.
119. Mathews SA, Kurien BT, Scofield RH. Oral manifestations of Sjögren's syndrome. J Dent Res. 2008; 87:308-18.
120. Panayiotakopoulos GD, Aroni K, Kyriaki D, Paikos S, Vouyioukas N, Vlachos A, et al. Paucity of Sjogren-like syndrome in a cohort of HIV-1-positive patients in the HAART era. Part II. Rheumatology (Oxford) 2003; 42: 1164-7.
121. Porter SR, Scully C, Hegarthy AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 97: 28-46.
122. Spina M, Sandri S, Tirelli U. Hodgkin's disease in HIVinfected individuals. Curr Opin Oncol. 1999; 11: 522-6.
123. Navarro CM, Shibli JA, Ferrari RB, d'Avila S, Sposto MR. Gingival primary extranodal non-Hodgkin's lymphoma as the first manifestation of acquired immunodeficiency syndrome. J Periodontol. 2008; 79: 562-6.
124. Berretta M, Cinelli R, Martellotta F, Spina M, Vaccher E, Tirelli U. Therapeutic approaches to AIDS-related malignancies. Oncogene. 2003; 22: 6646-59.
125. Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant 2008; 14: 59-66.
126. Miziara ID, Weber R. Oral lesions as predictors of highly active antiretroviral therapy failure in Brazilian HIV-infected children. J Oral Pathol Med. 2008; 37: 99-106.
127. Greenspan D, Canchola A, MacPhail L, Cheike B, Greenspan J. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet. 2001; 357:1411-2.
128. Hicks MJ, Flaitz CM, Carter AB, Cron SG, Rossmann SN, Simon CL, et al. Dental caries in HIV-infected children: a longitudinal study. Pediatr Dent. 2000; 22: 359-64.
129. Eldridge K, Gallagher JE. Dental caries prevalence and dental health behaviour in HIV infected children. Int J Paediatr Dent. 2000; 10: 19-26.
130. Ferris M, Burau K, Schweitzer AM, Mihale S, Murray N, Preda A, et al. The influence of disclosure of HIV diagnosis on time to disease progression in a cohort of Romanian children and teens. AIDS Care. 2007; 19: 1088-94.